Canton Strategic Holdings (CNTN) R&D In Process (2020 - 2021)
Canton Strategic Holdings posted quarterly R&D In Process of $178000.0 for Q4 2021, down 13.17% year-on-year from $205000.0 in Q4 2020, and down 13.17% on a QoQ basis from $205000.0 in Q4 2020.
Canton Strategic Holdings (CNTN) has 2 years of R&D In Process data on file, last reported at $178000.0 in Q4 2021.
- For the quarter ending Q4 2021, R&D In Process fell 13.17% year-over-year to $178000.0; the trailing twelve-month figure through Dec 2021 stood at $178000.0 (down 13.17% YoY), and the FY2021 full-year result was $178000.0, down 13.17% from the prior year.
- R&D In Process for Q4 2021 stood at $178000.0, down from $205000.0 in the prior quarter.
- Across five years, R&D In Process topped out at $205000.0 in Q4 2020 and bottomed at $178000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 178,000.00 |
| Dec 31, 2020 | 205,000.00 |